Georgios Trichas
Keine laufenden Positionen mehr
Karriereverlauf von Georgios Trichas
Ehemalige bekannte Positionen von Georgios Trichas
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
Acesion Pharma ApS
 Acesion Pharma ApS Pharmaceuticals: MajorHealth Technology Acesion Pharma ApS develops drugs for the treatment of atrial fibrillation (AF), the most common type of cardiac arrhythmia. The firm's technology blocks ion channel with a selective drug molecule constitutes a target for developing treatment of AF. The company was founded by Ulrik Svane S?rensen and Morten Grunnet in 2011 and is headquartered in Copenhagen, Denmark. | Direktor/Vorstandsmitglied | - | - |
Wellcome Trust Ltd. (Direct Investments)
 Wellcome Trust Ltd. (Direct Investments) Investment ManagersFinance Wellcome Trust Ltd. Direct Investments (WTDI) is a private equity and venture capital division of the Wellcome Trust Ltd. The firm was founded in 1936 by Sir Henry Wellcome. It’s headquartered in London, UK. | Private-Equity-Analyst | 11.02.2014 | - |
Ausbildung von Georgios Trichas
| University of Crete | Graduate Degree |
| University of Oxford | Graduate Degree |
Statistik
International
| Vereinigtes Königreich | 3 |
| Dänemark | 2 |
| Griechenland | 2 |
Operativ
| Graduate Degree | 2 |
| Private Equity Analyst | 1 |
| Director/Board Member | 1 |
Sektoral
| Consumer Services | 3 |
| Finance | 2 |
| Health Technology | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Private Unternehmen | 2 |
|---|---|
Wellcome Trust Ltd. (Direct Investments)
Wellcome Trust Ltd. (Direct Investments) Investment ManagersFinance Wellcome Trust Ltd. Direct Investments (WTDI) is a private equity and venture capital division of the Wellcome Trust Ltd. The firm was founded in 1936 by Sir Henry Wellcome. It’s headquartered in London, UK. | Finance |
Acesion Pharma ApS
Acesion Pharma ApS Pharmaceuticals: MajorHealth Technology Acesion Pharma ApS develops drugs for the treatment of atrial fibrillation (AF), the most common type of cardiac arrhythmia. The firm's technology blocks ion channel with a selective drug molecule constitutes a target for developing treatment of AF. The company was founded by Ulrik Svane S?rensen and Morten Grunnet in 2011 and is headquartered in Copenhagen, Denmark. | Health Technology |
- Börse
- Insiders
- Georgios Trichas
- Erfahrung
